Navigation Links
Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
Date:6/10/2011

BOCA RATON, Fla., June 10, 2011 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Activella® 0.5mg/0.1mg Tablets. The company currently markets an equivalent to Activella® 1.0mg/0.5mg Tablets, as (Estradiol/Norethindrone Acetate 1.0mg/0.5mg) Tablets.

Estradiol/Norethindrone Acetate Tablets is AB rated to Activella®, a brand product marketed by Novo Nordisk®, which is used as a treatment for moderate to severe vasomotor symptoms associated with menopause, and as prevention for postmenopausal osteoporosis. The original dose strength is also indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause in women who have a uterus.

The brand product had trailing 12 month sales of $28.5 million, based on industry sales data.

Breckenridge products are manufactured through partnerships with pharmaceutical manufacturers in state-of-the-art facilities throughout the world. Breckenridge maintains a stringent Quality Assurance program to ensure a consistent supply of quality pharmaceutical products.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders. www.bpirx.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Breckenridge Announces Approval of Anastrozole Tablets
2. Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
3. Breckenridge Pharmaceutical Enters Agreement with Oman Pharmaceutical Products Company LLC
4. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
5. Breckenridge Announces Approval of Letrozole Tablets
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... PROVO, Utah , May 3, 2016  Forté Elements, LLC (Forté) is excited ... use nutritional products that address the nutritional needs of recovery for a variety of ... its products. Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 Leading Economies ... Growth Ethiopia 10.2 Côte d,Ivoire 8.6 Uzbekistan 8 Ireland 7.8 India 7.3, ... TechSci Research, BRICS nations , which comprises of Brazil ... China and South Africa , registered the fastest ... economic slowdown in China , recession in Brazil ...
Breaking Medicine Technology:
(Date:5/3/2016)... Boston, MA (PRWEB) , ... May 03, 2016 , ... Registration is now open for ... Sunday, June 5, 2016 at the Hatch Memorial Shell on the Esplanade. The event regularly ... 6.2-miles. The 5K Run is a competitive, timed event fully sanctioned by the USA Track ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Elizabeth Murray ... pet parrots to join her with one on her shoulder and one on her ... a parking lot because of years of mitral valve prolapse. , The valves of ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... ... today announced that it is launching a new client service center in La ... Houston, Texas, and will provide the full range of Empyrean client services. , ...
(Date:5/3/2016)... ... , ... Ogawa World USA introduced the first of its kind Ogawa ... Application. The Smart 3D combines the best in technological advancement, design, and massage capability ... specialized massage program, each user has a tailored experience unparalleled by any other massage ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in West ... new and existing patients. Cosmetic dentistry allows patients to improve the aesthetics of their ... with some minor or more serious cosmetic flaws. These specials allow patients to achieve ...
Breaking Medicine News(10 mins):